目的分析麝香保心丸联合普罗布考对老年冠心病合并糖尿病患者血脂代谢及血管内皮功能的影响。方法前瞻性选取北京市朝阳区双桥医院2021年1月至2022年10月收治的老年冠心病合并糖尿病患者102例,按照随机数字表法分为观察组与对照组,每组...目的分析麝香保心丸联合普罗布考对老年冠心病合并糖尿病患者血脂代谢及血管内皮功能的影响。方法前瞻性选取北京市朝阳区双桥医院2021年1月至2022年10月收治的老年冠心病合并糖尿病患者102例,按照随机数字表法分为观察组与对照组,每组各51例,对照组采用常规疗法+普罗布考治疗,观察组在对照组基础上采用麝香保心丸治疗。治疗3个月后,统计分析两组临床疗效、血脂代谢指标[总胆固醇、甘油三酯、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、载脂蛋白(Apo)A1和ApoB]、血管内皮功能指标(内皮素-1、血栓素B2、一氧化氮)、心功能指标[左室收缩末内径(LVESD)、左室舒张末内径(LVEDD)、左室射血分数(LVEF)和左室质量指数(LVMI)]、血糖指标[空腹血糖(FBG)、糖化血红蛋白(GHb)及餐后2 h血糖(2 h PBG)]水平。结果观察组临床总有效率为94.12%,高于对照组(78.43%),差异有统计学意义(P<0.05)。治疗3个月后,观察组的总胆固醇、甘油三酯、LDL-C及ApoB水平分别为(5.15±0.88)mmol/L、(1.71±0.23)mmol/L、(3.33±0.71)mmol/L、(0.81±0.17)g/L,均低于对照组[(5.86±0.91)mmol/L、(2.13±0.26)mmol/L、(3.97±0.85)mmol/L、(1.08±0.18)g/L],HDL-C和ApoA1水平分别为(1.18±0.25)mmol/L、(1.44±0.25)g/L,均高于对照组[(0.96±0.22)mmol/L、(1.21±0.22)g/L],差异均有统计学意义(P<0.05)。治疗3个月后,观察组的内皮素-1及血栓素B2水平分别为(58.31±4.13)、(163.11±10.06)ng/L,均低于对照组[(62.11±4.41)、(179.31±11.11)ng/L],一氧化氮水平为(71.22±6.55)μmol/L,高于对照组[(67.58±5.61)μmol/L],差异均有统计学意义(P<0.05)。治疗3个月后,观察组的LVESD及LVMI分别为(35.13±2.23)mm、(109.85±11.29)g/m^(2),均低于对照组[(38.42±2.47)mm、(121.31±12.84)g/m^(2)],LVEDD、LVEF分别为(55.84±4.36)mm、(60.05±6.14)%,均高于对照组[(51.21±4.43)mm、(55.25±5.38)%],差异均有统计学意义(P<0.05)。治疗3个月后,观察组的FBG、GHb及2 h PBG水平分别为(6.41±1.01)mmol/L、(5.37±0.74)%、(8.20±1.34)mmol/L,均低于对照组[(7.31±1.04)mmol/L、(6.12±0.57)%、(9.68±1.22)mmol/L],差异均有统计学意义(P<0.05)。结论麝香保心丸联合普罗布考可有效改善老年冠心病合并糖尿病患者血脂代谢、血管内皮功能、心功能、血糖水平,临床综合疗效显著,值得临床予以推广应用。展开更多
目的系统评价麝香保心丸对动脉粥样硬化动物模型的干预作用。方法计算机检索建库至2023年7月18日在PubMed、Web of Science、EMbase、Cochrane Library、中国知网、维普、万方知识服务平台、中国生物医学文献数据库上公开发表的与麝香...目的系统评价麝香保心丸对动脉粥样硬化动物模型的干预作用。方法计算机检索建库至2023年7月18日在PubMed、Web of Science、EMbase、Cochrane Library、中国知网、维普、万方知识服务平台、中国生物医学文献数据库上公开发表的与麝香保心丸干预动脉粥样硬化模型动物实验相关文献。由2名研究者独立对文献进行筛选及资料提取,建立文献信息库,采用SYRCLE动物实验偏倚风险评估工具对纳入文献进行偏倚风险评价,使用RevMan 5.4软件进行Meta分析。结果经过筛选共纳入7篇文献进行Meta分析,与模型空白组相比麝香保心丸组可缩小主动脉斑块与血管腔面积比(SMD=-3.94,95%CI:-6.53~-1.36),降低血清低密度脂蛋白胆固醇水平(SMD=-2.86,95%CI:-4.21~-1.52),降低血清总胆固醇水平(SMD=-2.83,95%CI:-4.18~-1.47),降低血清三酰甘油水平(SMD=-2.80,95%CI:-4.57~-1.03)。麝香保心丸组与模型空白组相比血清高密度脂蛋白胆固醇水平差异无统计学意义(SMD=0.93,95%CI:-0.34~2.19)。结论本研究结果提示麝香保心丸干预动脉粥样硬化动物模型可缩小主动脉斑块面积,降低血清总胆固醇、三酰甘油、低密度脂蛋白胆固醇水平。其机制可能与抑制炎症反应、促进胆固醇流出调节脂代谢、保护血管内皮、缓解血管内皮凋亡、激活自噬等有关。上述结论仍需要纳入设计更为严谨的高质量文献不断补充验证。展开更多
目的观察替格瑞洛联合麝香保心丸对冠状动脉慢性完全闭塞(chronic total occlusion,CTO)患者血管内皮的再生作用。方法根据纳入排除标准选择2019年11月1日至2021年12月31日在医院心内科住院的60例经冠状动脉造影确诊为冠状动脉CTO的患者...目的观察替格瑞洛联合麝香保心丸对冠状动脉慢性完全闭塞(chronic total occlusion,CTO)患者血管内皮的再生作用。方法根据纳入排除标准选择2019年11月1日至2021年12月31日在医院心内科住院的60例经冠状动脉造影确诊为冠状动脉CTO的患者,按治疗方法分为两组,分别为常规组和观察组,每组30例。常规组给予常规治疗和替格瑞洛治疗,观察组在常规组基础上给予麝香保心丸治疗。比较两组治疗前和治疗12个月后血管炎症指数、血管内皮损伤和增殖标志物水平的变化,记录两组内皮舒张功能和侧支循环改善率。结果治疗前两组冠状动脉CTO患者的血管炎症指标、血管内皮损伤和增殖标志物比较差异均无统计学意义(P>0.05)。治疗后,观察组可溶性CD40配体(sCD40L)、高敏C反应蛋白(hs-CRP)、内皮素-1(ET-1)、血管性血友病因子(vWF)显著下降,与常规组相比,差异具有统计学意义(P<0.05);而内皮一氧化氮合酶(eNOS)、血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)和Jagged1蛋白均显著升高,与常规组相比,差异具有统计学意义(P<0.05);两组冠状动脉CTO患者的内皮舒张功能比较差异无统计学意义(P>0.05);观察组侧支循环良好率高于常规组(P<0.05)。结论替格瑞洛联合麝香保心丸治疗冠状动脉CTO患者可抑制血管炎症的表达,纠正其内皮功能障碍,促进内皮细胞增殖,改善冠状动脉CTO患者冠状动脉侧支循环。展开更多
Objective:To investigate the effect of Shexiang Baoxin Pill(麝香保心丸,SBP)on early hypertensive renal injury in rats and to explore the possible mechanism.Methods:Twelve-week-old spontaneous hypertensive rats(SHRs)wi...Objective:To investigate the effect of Shexiang Baoxin Pill(麝香保心丸,SBP)on early hypertensive renal injury in rats and to explore the possible mechanism.Methods:Twelve-week-old spontaneous hypertensive rats(SHRs)with high-salt diet(dietary containing 8%NaCl)were randomized into the SBP group[40 mg/(kg·d)],losartan potassium group[20 mg/(kg·d)]and saline group by stratified random sampling method,12 in each group.Blood pressure and urea albumin creatinine ratio were measured.After 10 weeks,the expression levels of serum creatinine(Scr),hypersensitive C-reactive protein(hs-CRP),interleukin(IL)-1β,IL-6,tumor necrosis factorα(TNF-α),and transforming growth factorβ(TGF-β)in serum were assessed.Kidney pathology periodate-schiff staining was performed.Semi-quantitative count of macrophage infiltration was determined by immunochemistry of CD68 staining.Real-time quantitative polymerase chain reaction and Western blot were performed to examine the mRNA and protein expressions of Toll-like receptor 4(TLR4),nuclear factorκB(NF-κB),monocyte chemokine peptide(MCP-1),inducible nitric oxide synthase(iNOS),and arginase-1(Arg-1).Results:SBP did not affect the mortality of SHR(P<0.05).SBP significantly reduced the level of elevated blood pressure of SHRs,but the effect was less significantly than that of losartan potassium.SBP decreased urine protein(P<0.01)and the expression levels of IL-1β,IL-6,TNF-α,and TGF-βin serum.The 22-week-old SHRs showed mild proliferation of glomerular endothelial cells,glomerular ischemic lesions,inflammatory cell infiltration in renal tubular interstitium and arteriosclerosis.Both SBP and losartan potassium had alleviated renal pathological change,and significantly reduced the infiltration of macrophage(P<0.05,P<0.01).SBP and losartan potassium decreased the expressions of TLR4,NF-κB,MCP-1,iNOS,and Arg-1.Conclusion:SBP significantly modified the early hypertensive renal injury by reducing inflammation,and the effect was similar to losartan potassium.展开更多
Objective:To evaluate the therapeutic efficacy of Shexiang Baoxin Pill combined with exercise in heart failure patients with preserved ejection fraction(HFpEF).Methods:Sixty patients with HFpEF were randomly divided i...Objective:To evaluate the therapeutic efficacy of Shexiang Baoxin Pill combined with exercise in heart failure patients with preserved ejection fraction(HFpEF).Methods:Sixty patients with HFpEF were randomly divided into group A(n=20),receiving Shexiang Baoxin Pill combined with home-based exercise training based on conventional drugs for 12 weeks;group B(n=20),receiving conventional drugs combined with home-based exercise training for 12 weeks;and group C(n=20),receiving conventional drug treatment only.Peak oxygen uptake(peakVO2),anaerobic threshold(AT),6-min walking test(6MWT),Pittsburgh Sleep Quality Index(PSQI),and SF-36 questionnaire(SF-36)results before and after treatment were compared among groups.Results:After the 12-week intervention,patients in group C showed significant declines in peakVO2,AT,6MWT,PSQI,and SF-36 compared with pre-treatment(P<0.01),while groups A and B both showed significant improvements in peakVO2,AT,6MWT,PSQI,and SF-36 results compared with pre-treatment(P<0.01).Compared with group C,patients in groups A and B showed significant improvements in peakVO2,AT,6MWT,PSQI,and SF-36(P<0.01).In addition,patients in group A showed more significant improvements in physical function,role-physical,vitality,and mental health scores on the SF-36 questionnaire,and PSQI scores than those in group B(P<0.01).Conclusions:Exercise training improved exercise tolerance,sleep quality and quality of life(QoL)in patients with HFpEF.Notably,Shexiang Baoxin Pill played an active role in sleep quality and QoL of patients with HFpEF.展开更多
文摘目的分析麝香保心丸联合普罗布考对老年冠心病合并糖尿病患者血脂代谢及血管内皮功能的影响。方法前瞻性选取北京市朝阳区双桥医院2021年1月至2022年10月收治的老年冠心病合并糖尿病患者102例,按照随机数字表法分为观察组与对照组,每组各51例,对照组采用常规疗法+普罗布考治疗,观察组在对照组基础上采用麝香保心丸治疗。治疗3个月后,统计分析两组临床疗效、血脂代谢指标[总胆固醇、甘油三酯、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、载脂蛋白(Apo)A1和ApoB]、血管内皮功能指标(内皮素-1、血栓素B2、一氧化氮)、心功能指标[左室收缩末内径(LVESD)、左室舒张末内径(LVEDD)、左室射血分数(LVEF)和左室质量指数(LVMI)]、血糖指标[空腹血糖(FBG)、糖化血红蛋白(GHb)及餐后2 h血糖(2 h PBG)]水平。结果观察组临床总有效率为94.12%,高于对照组(78.43%),差异有统计学意义(P<0.05)。治疗3个月后,观察组的总胆固醇、甘油三酯、LDL-C及ApoB水平分别为(5.15±0.88)mmol/L、(1.71±0.23)mmol/L、(3.33±0.71)mmol/L、(0.81±0.17)g/L,均低于对照组[(5.86±0.91)mmol/L、(2.13±0.26)mmol/L、(3.97±0.85)mmol/L、(1.08±0.18)g/L],HDL-C和ApoA1水平分别为(1.18±0.25)mmol/L、(1.44±0.25)g/L,均高于对照组[(0.96±0.22)mmol/L、(1.21±0.22)g/L],差异均有统计学意义(P<0.05)。治疗3个月后,观察组的内皮素-1及血栓素B2水平分别为(58.31±4.13)、(163.11±10.06)ng/L,均低于对照组[(62.11±4.41)、(179.31±11.11)ng/L],一氧化氮水平为(71.22±6.55)μmol/L,高于对照组[(67.58±5.61)μmol/L],差异均有统计学意义(P<0.05)。治疗3个月后,观察组的LVESD及LVMI分别为(35.13±2.23)mm、(109.85±11.29)g/m^(2),均低于对照组[(38.42±2.47)mm、(121.31±12.84)g/m^(2)],LVEDD、LVEF分别为(55.84±4.36)mm、(60.05±6.14)%,均高于对照组[(51.21±4.43)mm、(55.25±5.38)%],差异均有统计学意义(P<0.05)。治疗3个月后,观察组的FBG、GHb及2 h PBG水平分别为(6.41±1.01)mmol/L、(5.37±0.74)%、(8.20±1.34)mmol/L,均低于对照组[(7.31±1.04)mmol/L、(6.12±0.57)%、(9.68±1.22)mmol/L],差异均有统计学意义(P<0.05)。结论麝香保心丸联合普罗布考可有效改善老年冠心病合并糖尿病患者血脂代谢、血管内皮功能、心功能、血糖水平,临床综合疗效显著,值得临床予以推广应用。
文摘目的系统评价麝香保心丸对动脉粥样硬化动物模型的干预作用。方法计算机检索建库至2023年7月18日在PubMed、Web of Science、EMbase、Cochrane Library、中国知网、维普、万方知识服务平台、中国生物医学文献数据库上公开发表的与麝香保心丸干预动脉粥样硬化模型动物实验相关文献。由2名研究者独立对文献进行筛选及资料提取,建立文献信息库,采用SYRCLE动物实验偏倚风险评估工具对纳入文献进行偏倚风险评价,使用RevMan 5.4软件进行Meta分析。结果经过筛选共纳入7篇文献进行Meta分析,与模型空白组相比麝香保心丸组可缩小主动脉斑块与血管腔面积比(SMD=-3.94,95%CI:-6.53~-1.36),降低血清低密度脂蛋白胆固醇水平(SMD=-2.86,95%CI:-4.21~-1.52),降低血清总胆固醇水平(SMD=-2.83,95%CI:-4.18~-1.47),降低血清三酰甘油水平(SMD=-2.80,95%CI:-4.57~-1.03)。麝香保心丸组与模型空白组相比血清高密度脂蛋白胆固醇水平差异无统计学意义(SMD=0.93,95%CI:-0.34~2.19)。结论本研究结果提示麝香保心丸干预动脉粥样硬化动物模型可缩小主动脉斑块面积,降低血清总胆固醇、三酰甘油、低密度脂蛋白胆固醇水平。其机制可能与抑制炎症反应、促进胆固醇流出调节脂代谢、保护血管内皮、缓解血管内皮凋亡、激活自噬等有关。上述结论仍需要纳入设计更为严谨的高质量文献不断补充验证。
文摘目的观察替格瑞洛联合麝香保心丸对冠状动脉慢性完全闭塞(chronic total occlusion,CTO)患者血管内皮的再生作用。方法根据纳入排除标准选择2019年11月1日至2021年12月31日在医院心内科住院的60例经冠状动脉造影确诊为冠状动脉CTO的患者,按治疗方法分为两组,分别为常规组和观察组,每组30例。常规组给予常规治疗和替格瑞洛治疗,观察组在常规组基础上给予麝香保心丸治疗。比较两组治疗前和治疗12个月后血管炎症指数、血管内皮损伤和增殖标志物水平的变化,记录两组内皮舒张功能和侧支循环改善率。结果治疗前两组冠状动脉CTO患者的血管炎症指标、血管内皮损伤和增殖标志物比较差异均无统计学意义(P>0.05)。治疗后,观察组可溶性CD40配体(sCD40L)、高敏C反应蛋白(hs-CRP)、内皮素-1(ET-1)、血管性血友病因子(vWF)显著下降,与常规组相比,差异具有统计学意义(P<0.05);而内皮一氧化氮合酶(eNOS)、血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)和Jagged1蛋白均显著升高,与常规组相比,差异具有统计学意义(P<0.05);两组冠状动脉CTO患者的内皮舒张功能比较差异无统计学意义(P>0.05);观察组侧支循环良好率高于常规组(P<0.05)。结论替格瑞洛联合麝香保心丸治疗冠状动脉CTO患者可抑制血管炎症的表达,纠正其内皮功能障碍,促进内皮细胞增殖,改善冠状动脉CTO患者冠状动脉侧支循环。
文摘Objective:To investigate the effect of Shexiang Baoxin Pill(麝香保心丸,SBP)on early hypertensive renal injury in rats and to explore the possible mechanism.Methods:Twelve-week-old spontaneous hypertensive rats(SHRs)with high-salt diet(dietary containing 8%NaCl)were randomized into the SBP group[40 mg/(kg·d)],losartan potassium group[20 mg/(kg·d)]and saline group by stratified random sampling method,12 in each group.Blood pressure and urea albumin creatinine ratio were measured.After 10 weeks,the expression levels of serum creatinine(Scr),hypersensitive C-reactive protein(hs-CRP),interleukin(IL)-1β,IL-6,tumor necrosis factorα(TNF-α),and transforming growth factorβ(TGF-β)in serum were assessed.Kidney pathology periodate-schiff staining was performed.Semi-quantitative count of macrophage infiltration was determined by immunochemistry of CD68 staining.Real-time quantitative polymerase chain reaction and Western blot were performed to examine the mRNA and protein expressions of Toll-like receptor 4(TLR4),nuclear factorκB(NF-κB),monocyte chemokine peptide(MCP-1),inducible nitric oxide synthase(iNOS),and arginase-1(Arg-1).Results:SBP did not affect the mortality of SHR(P<0.05).SBP significantly reduced the level of elevated blood pressure of SHRs,but the effect was less significantly than that of losartan potassium.SBP decreased urine protein(P<0.01)and the expression levels of IL-1β,IL-6,TNF-α,and TGF-βin serum.The 22-week-old SHRs showed mild proliferation of glomerular endothelial cells,glomerular ischemic lesions,inflammatory cell infiltration in renal tubular interstitium and arteriosclerosis.Both SBP and losartan potassium had alleviated renal pathological change,and significantly reduced the infiltration of macrophage(P<0.05,P<0.01).SBP and losartan potassium decreased the expressions of TLR4,NF-κB,MCP-1,iNOS,and Arg-1.Conclusion:SBP significantly modified the early hypertensive renal injury by reducing inflammation,and the effect was similar to losartan potassium.
基金Supported by the Chinese Association of Integrative MedicineHutchison Research Fund (No. HMP2005002P)。
文摘Objective:To evaluate the therapeutic efficacy of Shexiang Baoxin Pill combined with exercise in heart failure patients with preserved ejection fraction(HFpEF).Methods:Sixty patients with HFpEF were randomly divided into group A(n=20),receiving Shexiang Baoxin Pill combined with home-based exercise training based on conventional drugs for 12 weeks;group B(n=20),receiving conventional drugs combined with home-based exercise training for 12 weeks;and group C(n=20),receiving conventional drug treatment only.Peak oxygen uptake(peakVO2),anaerobic threshold(AT),6-min walking test(6MWT),Pittsburgh Sleep Quality Index(PSQI),and SF-36 questionnaire(SF-36)results before and after treatment were compared among groups.Results:After the 12-week intervention,patients in group C showed significant declines in peakVO2,AT,6MWT,PSQI,and SF-36 compared with pre-treatment(P<0.01),while groups A and B both showed significant improvements in peakVO2,AT,6MWT,PSQI,and SF-36 results compared with pre-treatment(P<0.01).Compared with group C,patients in groups A and B showed significant improvements in peakVO2,AT,6MWT,PSQI,and SF-36(P<0.01).In addition,patients in group A showed more significant improvements in physical function,role-physical,vitality,and mental health scores on the SF-36 questionnaire,and PSQI scores than those in group B(P<0.01).Conclusions:Exercise training improved exercise tolerance,sleep quality and quality of life(QoL)in patients with HFpEF.Notably,Shexiang Baoxin Pill played an active role in sleep quality and QoL of patients with HFpEF.
